CCDC63

Across TCGA pan-cancer cohorts, CCDC63 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CCDC63 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CCDC63 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC63 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

THYM, UCEC, and ESCA are the cancer types where CCDC63 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	All	0.971	0.606	.002	22	view →
ESCA	DFS	Median	II,III,IV	0.173	0.525	.017	15	view →
BLCA	OS	Median	IV	0.153	0.599	.018	9	view →
LIHC	DFS	Median	II,III,IV	0.080	0.427	.019	6	view →
COAD	OS	Median	III,IV	0.239	0.791	.014	6	view →
LUAD	DFS	Median	II,III,IV	0.178	0.721	.008	6	view →
GBM	DFS	Median	All	1.000	0.204	.042	3	view →
STAD	DFS	Median	III,IV	1.000	0.330	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CCDC63–THYM (OS)

Open the THYM breakdown →